Body Acceptance After Baby Intervention (BABI)

February 12, 2026 updated by: Northeastern University
The purpose of this study is to learn if a novel online single-session intervention can help improve body dissatisfaction in new moms. The active intervention condition, Body Acceptance After Baby (BABI), uses acceptance-based skills to help participants cope with body dissatisfaction. BABI will be evaluated against another active intervention condition (a brief infographic that provides psychoeducation about body image during postpartum) and a waitlist control condition.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
375

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • United States
    • Massachusetts
      • Boston, Massachusetts, United States, 02115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Individuals must:

  • Be currently residing in the U.S.
  • Be able to read and write in English
  • Be aged 18 or above
  • Identify as a woman
  • Have given birth to a live infant in the past year
  • Endorse dissatisfaction with their appearance (i.e., in answering the question "Indicate how satisfied you are with your overall appearance" they must answer neutral, mostly dissatisfied, or very dissatisfied)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Body Acceptance After Baby Intervention (BABI)
The active condition, BABI, includes (1) psychoeducation about body image during postpartum; (2) psychoeducation about acceptance; (3) an activity to practice "unhooking" (cognitive defusion skill); (4) a values clarification exercise; (5) a peer advice activity (participants give advice in response to vignettes of new moms who are struggling with body image); and (6) the creation of a personalized action plan. BABI is designed to take approximately 30 minutes.
Behavioral: Body Acceptance after Baby (BABI)
BABI is an online, self-directed single-session intervention designed to improve body dissatisfaction in postpartum moms (up to one year after delivery) aged 18 or older.
Experimental: Postpartum Body Image Infographic
Participants will read a brief infographic that includes (1) psychoeducation about body image and the harms of "bounce-back" culture during postpartum and (2) ways to improve body image. This infographic is designed to be read in approximately 2 minutes.
Behavioral: Postpartum Body Image Infographic
The postpartum body image infographic is an online pamphlet that provides psychoeducation about body image during postpartum.
No Intervention: Waitlist Control
This group will receive no intervention, but will be given access to both active conditions at the end of follow-ups.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Postpartum body image
Time Frame: Baseline, 1 month, 3 months
Postpartum body image will be measured using the Body Image in Pregnancy Scale adapted for postpartum. Only the following subscales will be measured: (1) Preoccuptation with Physical Appearance; (2) Prioritization of Appearance over Function; (3) Appearance-Related Behavioral Avoidance. Subscales range from 1-5 with higher scores indicating greater body image disturbance.
Baseline, 1 month, 3 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Body appreciation
Time Frame: Baseline, 1 month, 3 months
Body Appreciation will be measured using The Body Appreciation Scale-2 Short Form. Scores range from 3-15 with higher scores indicating greater body appreciation.
Baseline, 1 month, 3 months
Psychological flexibility
Time Frame: Baseline, 1 month, 3 months
Psychological flexibility will be measured with the Comprehensive assessment of Acceptance and Commitment Therapy processes (CompACT). Scores range from 0-138 with higher scores indicating greater psychological flexibility. Subscales can also be calculated to measure (1) Openness to Experience, (2) Behavioral Awareness, and (3) Valued Action.
Baseline, 1 month, 3 months
Postpartum depression
Time Frame: Baseline, 1 month, 3 months
Postpartum depression will be measured with the Edinburgh Postnatal Depression Scale (EPDS). Scores range from 0-30 with higher scores indicating greater depressive symptoms.
Baseline, 1 month, 3 months
Eating disorder symptoms
Time Frame: Baseline, 1 month, 3 months
Eating disorder symptoms will be measured with the Eating Disorder Examination Questionnaire Short (EDE-QS). Scores range from 0-36 with higher scores indicating greater severity of eating disorder symptoms.
Baseline, 1 month, 3 months
Intuitive eating
Time Frame: Baseline, 1 month, 3 months
Intuitive eating will be measured with the Intuitive Eating Scale-3 (IES-3) . Each item ranges from 1-5 and can be averaged to obtain a global score with higher scores indicating greater intuitive eating. Subscale scores (Unconditional Permission to Eat; Eating for Physical Reasons; Reliance on Hunger and Satiety Cues; Body-Food Choice Congruence) can also be calculated.
Baseline, 1 month, 3 months
Breastfeeding self-efficacy
Time Frame: Baseline, 1 month, 3 months
Breastfeeding self-efficacy will be measured with the Breastfeeding Self-Efficacy Scale (BSES-SF). Scores range from 14-70 with higher scores indicating greater self-efficacy.
Baseline, 1 month, 3 months
Bottle-feeding self-efficacy
Time Frame: Baseline, 1 month, 3 months
Bottle-feeding self-efficacy will be measured with the Bottle Feeding Self-Efficacy Scale. Scores range from 20-100 with higher scores indicating greater self-efficacy.
Baseline, 1 month, 3 months
State mood and body image
Time Frame: Baseline
Visual analog scales will be used to measure state anxiety, negative affect, positive affect, appearance satisfaction, weight satisfaction, muscle tone satisfaction, confidence, body acceptance, body positivity, anger, body functionality appreciation, body appreciation, broad concept of beauty (body sizes and body shapes) and body positive protective filter. Each item ranges from 0-100 with greater scores indicating greater levels of the respective variable.
Baseline
Hopelessness
Time Frame: Baseline
Hopelessness will be measured with the Beck Hopelessness Scale - 4-item version (BHS). Each item ranges from 0-3. Items are averaged to obtain a total score with higher scores indicating greater hopelessness.
Baseline

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Acceptability
Time Frame: Baseline
To measure intervention acceptability we will use the The Program Feedback Scale (PFS). The PFS asks participants to rate agreement with seven statements about the acceptability of the SSI (e.g. "I enjoyed the program") on a five-point scale. Higher scores reflect greater acceptability for each item.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Northeastern University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 20, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 1, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 14, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 12, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 20, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 20, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 12, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 24-11-25

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings